FDA approves new HIV and Hepatitis C drugs

In Health and Safety, Research by Paul MartinLeave a Comment

The United States’ Food and Drug Administration has just approved a new drug to fight HIV in combination with other antiretrovirals that are already on the market.  The drug is called Edurant, and it was made by New Jersey based Tibotec Therapeutics.  It works by blocking the HIV from replicating and is part of a class of drugs known as non-nucleoside reverse transcriptase inhibitor.

“Patients may respond differently to various HIV drugs or experience varied side effects,” said Edward Cox, director of the office of antimicrobial products in the FDA’s Center for Drug Evaluation and Research.

“FDA’s approval of Edurant provides an additional treatment option for patients who are starting HIV therapy.”


The FDA also approved a long awaited drug for the treatment of Hepatitis C, which was developed by Vertex Pharmaceuticals.  The drug is called Incivek, and it is so effective that the chances of a person being cured of the disease double with its’ use.  This drug works in combination with others such as ribavirin and pegylated interferon.  It was unanimously approved by the FDA, and Vertex founder and former CEO Joshua Boger remarked that this is “a great day for patients that we at Vertex envisioned almost 18 years ago.”


Paul Martin

Paul Martin

I am the Director of Multimedia at ProTrainings, as well as the primary blogger here. I take care of the video editing, graphic design and corporate branding that you see on every video and every page on this site, as well as at ProCPR®, ProFirstAid®, ProBloodborne, StudentCPR, etc. My work is literally everywhere that ProTrainings goes. I also handle our Twitter accounts, so be sure to follow us there, if you use twitter! You can be sure that I’m not just an average joe writing this blog, but one of the founders of the company.

More Posts - Website

Follow Me:
TwitterFacebookLinkedInGoogle Plus

Leave a Reply